Luminespib |
Inhibitor of HSP90AA1, HSP90AB1
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| HSP90AA1 |
|
|
| HSP90AB1 |
|
|
Inhibitor
up to 1 uM
Selectivity
In Vitro Selectivity Assessment
Potency: IC50 - GRP94 535 nM, TRAP-1 85 nM
Potency Assay Off-Target:
Fluorescence polarisation (FP) competitive binding assay
Selectivity Assessment Description:
At 10 uM there is no inhibition of human HSP72 ATPase or decatenation activity of human topoisomeras ...
Potency Cellular
In Vitro
HSP90AA1
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? No
DOI Reference: 10.1158/1078-0432.CCR-05-0518
HSP90AB1
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? No
DOI Reference: 10.1158/1078-0432.CCR-05-0518
In Vivo Validations
Mouse
Dose: 50 mg/Kg
Route of delivery:
Intraperitoneal, Intravenous
Plasma half life:
15 h in Tumor, 2 h in Plasma
Systemic clearance:
0.143 L/h in Plasma 0.020 L/h in Tumor
Target engagement assay:
Therapeutic activity was tested in established human xenografts (colon, glioblastoma, breast, ovarian, and prostate) providing evidence of antitumour activity.
Evidence of HSP90 inhibition comes from changes in the biomarkers as reported in Banerji et al 2005 (DOI: 10.1158/1078-0432.CCR-05-0518)
DOI Reference: 10.1158/1078-0432.CCR-05-0518
Chemical Information
| Molecular Formula | C26H31N3O5 |
| SMILEs | CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1 |
| InChI | InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32) |
| Molecular weight | 465.23 Da |
| AlogP | 0.0 |
| HBond acceptors | 8 |
| HBond donors | 3 |
| Atoms | 65 |
References
Publications
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.